目的 探讨桂枝茯苓胶囊联合孕三烯酮治疗子宫腺肌症的临床效果。方法 选取2012年6月-2016年6月在鹤壁京立医院就诊的126例子宫腺肌症患者，随机分为对照组和治疗组，每组各63例，对照组患者口服孕三烯酮胶囊，月经第1天和第5天各1片，以后2次/周，2.5 mg/次，且服药时间一致。治疗组患者在对照组的基础上口服桂枝茯苓胶囊，3粒/次，3次/d。两组患者均持续治疗6个月。观察治疗后两组患者的临床效果，比较分析患者治疗前后两组患者子宫体积、痛经评级、月经量变化指标以及血清CA125和血管内皮生长因子（VEGF）水平。结果 治疗后，对照组和治疗组的总有效率分别为66.67%、88.89%，两组患者临床总有效率比较差异具有统计学意义（P<0.05）。治疗后，两组患者痛经评级，子宫体积，月经量PBAC评分均比治疗前显著下降，同组比较差异具有统计学意义（P<0.05）；且治疗后治疗组患者这些指标要显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清CA125、VEGF水平均显著下降（P<0.05），且治疗后治疗组患者血清CA125、VEGF水平显著低于对照组（P<0.05）。治疗过程中，对照组患者不良反应发生率为31.75%，显著高于治疗组的14.29%，两组不良反应发生情况比较差异具有统计学意义（P<0.05）。结论 桂枝茯苓胶囊联合孕三烯酮治疗子宫腺肌症临床效果较好，可明显改善患者临床症状，降低血清免疫学参数，且不良反应较少，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Guizhi Fuling Capsules combined with gestrinone in treatment of adenomyosis. Methods Patients (126 cases) with adenomyosis in Hebi Jingli Hospital from June 2012 to June 2016 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were po administered with Gestrinone Capsules, each tablet on day 1 and 5 of menstruation, then twice every week, 2.5 mg/time, and kept medication time consistent. Patients in the treatment group were po administered with Guizhi Fuling Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the uterine volume, dysmenorrhea grade, menstrual volume, serum CA125 and VEGF level in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 66.67% and 88.89%, respectively, and there was difference between two groups (P < 0.05). After treatment, the dysmenorrhea grade, uterine volume, and menstrual volume PBAC score in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the CA125 and VEGF level in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment, the adverse reaction rate in the control group was 31.75%, which was significantly higher than that (14.29%) in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Guizhi Fuling Capsules combined with gestrinone has good clinical effects in treatment of adenomyosis, can significantly improve the clinical symptoms and decrease serum immunological parameters with less adverse reactions, which has a certain clinical application value.